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a  b  s  t  r  a  c  t
Fumarate  hydratases  (FHs;  EC  4.2.1.2)  are  enzymes  that  catalyze  the  reversible  hydration  of  fumarate
to  S-malate.  Parasitic  protists  that  belong  to the  genus  Leishmania  and  are  responsible  for  a  complex  of
vector-borne  diseases  named  leishmaniases  possess  two  genes  that  encode  distinct  putative  FH  enzymes.
Genome  sequence  analysis  of  Leishmania  major  Friedlin  reveals  the  existence  of  genes  LmjF24.0320  and
LmjF29.1960  encoding  the  putative  enzymes  LmFH-1  and  LmFH-2,  respectively.  In  the  present  work,  the
FH activity  of  both  L. major  enzymes  has  been  conﬁrmed.  Circular  dichroism  studies  suggest  important
differences  in  terms  of secondary  structure  content  when  comparing  LmFH  isoforms  and  even larger  dif-
ferences when  comparing  them  to  the  homologous  human  enzyme.  CD melting  experiments  revealed  thatell compartmentalization
inetics
tructure
both LmFH  isoforms  are  thermolabile  enzymes.  The  catalytic  efﬁciency  under  aerobic  and  anaerobic  envi-
ronments  suggests  that  they  are  both  highly  sensitive  to  oxidation  and  damaged  by oxygen.  Intracellular
localization  studies  located  LmFH-1  in the mitochondrion,  whereas  LmFH-2  was  found  predominantly
in  the  cytosol  with possibly  also  some  in  glycosomes.  The  high  degree  of  sequence  conservation  in dif-
ferent  Leishmania  species,  together  with  the  relevance  of  FH activity  for the  energy  metabolism  in these
parasites  suggest  that  FHs  might  be exploited  as  targets  for broad-spectrum  antileishmanial  drugs.
© 2012 Elsevier B.V. Open access under the Elsevier OA license. . Introduction
Human leishmaniases are parasitic diseases caused by about 20
pecies of the genus Leishmania, obligate intramacrophage protists
ransmitted by about 30 species of phlebotomine sandﬂies [1].  The
ain clinical manifestations of leishmaniases are ulcerative skin
esions, destructive mucosal inﬂammation, and disseminated vis-
eral infection [2].  Leishmaniases, classiﬁed as neglected tropical
iseases, are a global health problem and threaten 350 mil-
ion people in 88 countries around the world. The World Health
rganization has estimated that 12 million people are currently
nfected, with 2 million new cases each year. There is no vac-
ine available for preventing leishmaniasis [3] and the current
Abbreviations: FH, fumarate hydratase; LmFH, fumarate hydratase from Leish-
ania major;  LmFH-1, fumarate hydratase from L. major encoded by LmjF24.0320
ene; LmFH-2, fumarate hydratase from L. major encoded by LmjF29.1960 gene.
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Open access under the Elsevier OA license. treatment is mainly based on pentavalent antimonials and sec-
ond line drugs such as amphotericin B and pentamidine. However,
the current antileishmanial therapy displays serious side effects
due to toxicity, the costs of adequate therapy are high and cases
of drug resistance have already been reported. There is an urgent
need for development of novel, efﬁcacious, safe and affordable
anti-parasitic agents to prevent, control and treat leishmani-
ases.
Genome sequencing projects of Leishmania major [4],  Leishma-
nia infantum [5] and Leishmania braziliensis [5] have been completed
and have allowed to understand similarities and differences among
different Leishmania species, thus making an important contribu-
tion to the identiﬁcation of new drug targets and vaccine candidates
for leishmaniases [6].
In the particular case of the study reported in this paper, the
analysis of the available L. major genome sequence has led to the
identiﬁcation of two genes, LmjF24.0320 and LmjF29.1960, which
encode distinct putative fumarate hydratases (FHs; EC 4.2.1.2),
enzymes also called fumarases, which catalyze the stereospeciﬁc
reversible hydration of fumarate to S-malate.






























































spectroscopy at 280 nm [21] (ε280nm = 42,790 M−1 cm−1 for LmFH-1
and ε280nm = 65,500 M−1 cm−1 for LmFH-2). All steps of the puriﬁ-6 P.R. Feliciano et al. / International Journa
Fumarate hydratases (FHs) have been initially grouped into
wo classes depending on their thermal stability, relative sub-
nit arrangement, and metal requirement [7].  Class I fumarate
ydratases are oxygen-sensitive, thermolabile, homodimeric, Fe–S
luster containing enzymes with a molecular mass of approxi-
ately 120 kDa, and can occur in bacteria (fumA and fumB from
scherichia coli [7]) and at least several groups of unicellular
ukaryotes [8].  Class II fumarate hydratases are oxygen-insensitive,
hermostable, iron-independent, homotetrameric enzymes of
00 kDa, and occur in bacteria (fumC from E. coli [7]) and
igher eukaryotes such as mammals [9,10].  Although functionally
elated, FHs from classes I and II exhibit low sequence identity
around 20%). Recently, a novel group of fumarate hydratases
as been described in the literature as two-subunit FHs based
n sequence identity to class I fumarate hydratases [11,12]. Two-
ubunit fumarate hydratases are oxygen-sensitive, thermostable,
e–S cluster-containing heterodimeric proteins with two  different
ubunits ( and  subunit).
In general, eukaryotic cells express two isoforms of fumarate
ydratase: a cytosolic and a mitochondrial one. The cytosolic iso-
orm has been suggested to be involved in the production of
umarate that acts as a substrate for dihydroorotate dehydroge-
ase, an enzyme involved in the de novo pyrimidine biosynthesis
athway [13,14]. Furthermore, the cytosolic fumarate hydratase
as also been described as being able to migrate from the cytosol
o the nucleus where it plays a key role in DNA repair. In humans,
he deﬁciency of this fumarate hydratase is related to a tumor sus-
eptibility syndrome, Hereditary Leiomyomatosis and Renal Cell
ancer (HLRCC) [15].
The mitochondrial isoform participates in the tricarboxylic
cid (TCA) cycle and may  also take part in the succinic fermen-
ation pathways providing fumarate for the enzyme fumarate
eductase [16]. In humans, mutations in the mitochondrial
umarate hydratase are responsible for the Fumarase Deﬁciency
isease, also known as fumaric aciduria, described as a severe
ncephalopathy that leads to seizures and developmental delay
17].
While there are a wide range of studies focusing on the human
nzymes, from biophysicochemical and structural characterization
o their involvement in cellular functions, there is very limited
nformation available on the possible role of fumarate hydratases
n other organisms. To our knowledge, the data available to Try-
anosomatidae, the protist family comprising parasites such as
eishmania and Trypanosoma, are limited to a RNA interference
tudy that showed that fumarate hydratase activity is essential
or the viability of the insect-stage speciﬁc procyclic form of
he human sleeping-sickness causing parasite Trypanosoma brucei
18].
It is our interest to investigate the role of fumarate hydratases
n Leishmania. As a ﬁrst step towards this goal, we report here
he cloning, heterologous expression, puriﬁcation and character-
zation of the products of two genes from L. major (LmjF24.0320
nd LmjF29.1960), each encoding a putative fumarate hydratase
nzyme, LmFH-1 and LmFH-2, respectively, of which we conﬁrmed
he predicted activity. Subcellular localization studies showed that
he LmFH isoforms are localized in different cell compartments,
mFH-1 being mitochondrial and LmFH-2 showing its localization
ssentially in the cytosol and possibly also some in glycosomes,
he characteristic peroxisome-like organelles of Kinetoplastea, the
rotist clade to which trypanosomatids belong. The biophysical
nd biochemical characterization showed that LmFH-1 and LmFH-2
ollow Michaelis–Menten kinetics and display differences in pro-
ein folding. The study here presented provides the ﬁrst data on
umarate hydratases from Leishmania, signiﬁcantly contributing to
he understanding of the functional role of these enzymes in that
arasite.ological Macromolecules 51 (2012) 25– 31
2. Materials and methods
2.1. Cloning, expression and puriﬁcation of recombinant LmFH
isoforms
The open-reading frames encoding full-length LmFH
isoforms were ampliﬁed by PCR using as a template
genomic DNA, isolated from promastigote forms of L. major
Friedlin. Two pairs of oligonucleotides, forward primer 5′-
GACGACGAATTCATGCTCCGCCGCCTTGC-3′ and reverse primer
5′-GACGACGCGGCCGCACTAGAGCTGTTCGAAGAAGTCGTTG-3′, and
forward primer 5′-GACGACGAATTCATGTCTCTGTGCGACCAGTGC-
3′ and reverse primer 5′-GACGACGCGGCCGCATCACGCAA
GCGTCTTCGAGTACAT-3′, were, respectively, based on the
sequences of the genes putatively annotated as FHs  in the L.
major genome database (accession codes LmjF24.0320 and
LmjF29.1960) and designed to introduce EcoRI and NotI restriction
sites (underlined). The PCR for each FH gene was  carried out in
a 50 l volume containing 0.4 M of each primer, 0.5 ng l−1 of
genomic DNA, 2 mM MgSO4 (Invitrogen), 0.2 mM dNTP mixture
(Invitrogen) and 1 U of Platinum Taq DNA polymerase High Fidelity
(Invitrogen). The reactions were performed by initial denaturation
at 94 ◦C for 120 s followed by 25 cycles of 94 ◦C for 30 s (denatu-
ration), 60 ◦C for 30 s (annealing), and 68 ◦C for 120 s (elongation),
ﬁnal extension was performed at 68 ◦C for 10 min. The resulting
PCR products were visualized on a 0.8% agarose gel stained with
ethidium bromide, gel extracted, and puriﬁed using a QIAquick Gel
Extraction Kit (Qiagen). The puriﬁed PCR products were digested
with EcoRI (Invitrogen) and NotI (Invitrogen) to provide cohesive
ends and ligated to digested expression vector pET-28a (Novagen)
using T4 DNA ligase (Invitrogen). E. coli DH5 competent cells
were transformed with the ligated mixtures, clones selected and
the plasmids propagated [19]. Plasmid DNA was extracted from
the transformants using the QIAprep spin Miniprep Kit (Qiagen)
and the sequences of the cloned genes were conﬁrmed by DNA
sequencing. One sequenced clone of each FH gene was selected
and used to transform E. coli strain BL21(DE3) cells. The full-length
LmFH isoforms were expressed as histidine-tagged fusion proteins.
A single colony of E. coli BL21(DE3) cells harboring a recombi-
nant LmFH plasmid was used to inoculate 10 ml  Luria-broth
(LB) medium supplemented with 30 g ml−1 kanamycin and the
culture was grown for 16 h at 37 ◦C with shaking. The culture was
then 1:100 diluted with LB containing 30 g ml−1 kanamycin and
grown at 37 ◦C till the OD600nm reached 0.5–0.6. The cells were
then induced with 0.25 mM isopropyl -d-thiogalactopyranoside
(IPTG), the culture supplemented with 2 mM cysteine, 0.2 mg  ml−1
ferrous sulfate, 0.2 mg  ml−1 ferric citrate [20], and growth was
continued for 24 h at 18 ◦C. The induced culture was  harvested by
centrifugation at 6800 × g for 10 min. The bacterial pellet obtained
from 1 l of culture was  frozen at −20 ◦C. The cells were suspended
into 20 ml  buffer A (50 mM sodium phosphate, pH 8.5, 300 mM
NaCl) with 1 mM phenylmethylsulfonyl (PMSF) and lysed by
sonication with 10 × 30 s bursts (with 30 s intervals between each
burst) using a Misonix XL 2000 sonicator ﬁtted with a microtip
probe and set at power setting 4. The crude extract was  clariﬁed by
centrifugation at 15,700 × g for 15 min  at 4 ◦C. The enzyme LmFH,
present in the soluble fraction, was loaded on a 2 ml  column of
Ni–NTA resin (Qiagen) equilibrated with buffer A. The column was
then washed with a step gradient of imidazole from 0 to 50 mM in
buffer A. The recombinant LmFH was  eluted with buffer A contain-
ing 100 mM imidazole; the purity of the protein was checked by
12% SDS–PAGE and its concentration determined by UV absorbancecation were performed in either aerobic or anaerobic conditions,
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.2. Circular dichroism (CD)
Far-UV CD spectra (195–250 nm)  of the LmFH isoforms were
easured in a JASCO J-715 spectropolarimeter equipped with a
emperature controller. The measurements were performed with
emperature variation (10–94 ◦C), 0.2 mg  ml−1 protein in 4–5 mM
ris, pH 8.5, 4–5 mM NaCl and using a 1 mm  path length quartz
ell, 100 nm min−1 scanning speed, 2 nm band width, 2 s response
ime, 0.2 nm data pitch. At the end of each thermal scan, the
mFH-1 and LmFH-2 samples were allowed to cool to 10 ◦C before
escanning to assess reversibility/irreversibility of the unfolding
eaction. The ﬁnal spectrum was the average of four scans. The
D spectrum was converted to mean molar ellipticity per residue
] = ( M0)/(10 lc), where  is the experimental ellipticity in mil-
idegrees, M0 is the mean molecular weight per residue (M0 = 115),
 is the protein concentration (mg  ml−1), and l is the path length
cm).
.3. Optimum pH and enzymatic kinetics of LmFH isoforms
All studies were performed with the oligo-histidine tagged
nzyme; the LmFH activity measurements were carried out in
ither aerobic or anaerobic conditions, in the latter case using a
love box supplied with nitrogen gas. The fumarate production
r consumption was measured spectrophotometrically at 250 nm
ε = 1450 M−1 cm−1) at room temperature in a Hitachi U-2800 spec-
rophotometer. The pH dependence of activity was determined by
arying the pH of the reaction mixtures (50 mM  sodium acetate,
H 4 and 5, 50 mM sodium cacodylate, pH 6.2, 50 mM Tris, pH 7, 8,
nd 9, 50 mM glycine/NaOH, pH 10, 50 mM NaHCO3/NaOH, pH 11,
0 mM KCl/NaOH, pH 12, with 150 mM NaCl) using 1 mM substrate,
-malate or fumarate, in a total volume of 1 ml.  The kinetic param-
ters, Vmax and Km, were determined from a Lineweaver–Burk plot
tted to the experimental data obtained by varying the concentra-
ion of S-malate using 0.125, 0.25, 0.5, 1, 2, 4 and 8 mM,  and varying
he concentration of fumarate using 31.25, 62.5, 125, 250, 500 and
000 M.  Kinetic assays were performed in a reaction mixture con-
aining 50 mM Tris, pH 8.5 (LmFH-1) and 9 (LmFH-2), 150 mM NaCl
ith substrate, S-malate or fumarate, in a total volume of 1 ml.  All
tudies were performed with the LmFH (40 g ml−1 ﬁnal concen-
ration) in 50 mM Tris, pH 8.5, 150 mM NaCl.
.4. Production of puriﬁed polyclonal antibodies to LmFH
soforms
The production of polyclonal antisera against LmFH-1 and
mFH-2 was performed by immunization of rabbits with 800 g
f recombinant protein in PBS, pH 7.4. Rabbits were given initial
ntradermal injections at ﬁve spots in dorsal muscles with recom-
inant protein emulsiﬁed in complete Freund’s adjuvant. At 15,
0 and 45 days after the initial injection, the rabbits were given
ooster intramuscular injections with the same antigen emulsi-
ed with Freund’s incomplete adjuvant. Before each immunization,
lood was collected, clotted at room temperature for 1 h, cen-
rifuged at 450 × g for 15 min  at 4 ◦C, and the sera were stored
t −20 ◦C. 15 days after the last immunization, antibodies in the
era were precipitated with 40% ammonium sulfate, redissolved
nd dialyzed against PBS, pH 7.4, for 3 days. IgG antibodies against
mFH-1 and LmFH-2 were puriﬁed by afﬁnity chromatography on
 protein G column (IgG anti-LmFH-1 and IgG anti-LmFH-2). The
olumn was equilibrated and washed with PBS, pH 7.4. The anti-
odies were eluted with 0.2 M glycine pH 2.8 and neutralized with
 M K2HPO4 pH 10. The development of anti-LmFH-2 and anti-
mFH-2 polyclonal antibodies was monitored by enzyme-linked
mmunosorbent assay (ELISA).ological Macromolecules 51 (2012) 25– 31 27
2.5. Subcellular localization in Leishmania mexicana mexicana
2.5.1. Parasites
Leishmania mexicana mexicana promastigotes
(MHOM/BZ/84/BEL46) were grown in vitro at 28 ◦C in a semi-
deﬁned medium (SDM-79) supplemented with 10% fetal calf
serum.
2.5.2. Subcellular fractionation by treatment of cells with
digitonin
Parasites were centrifuged at 400 × g for 10 min, washed twice
in SHE buffer (25 mM  HEPES, pH 7.4, 250 mM sucrose, 1 mM EDTA)
containing a protease inhibitor cocktail (1 M pepstatin, 1 M leu-
peptin, 10 M AEBSF, 100 M EDTA) and resuspended in 1 ml  of
the same solution. 100 l of cell suspension were incubated with
0.1% Triton X-100 (v/v) at 4 ◦C for 20 min  and the total protein con-
centration was estimated by the Bradford assay [22]. Aliquots of
cell suspensions containing 300 g of protein were diluted in HBSS
buffer (1.3 mM CaCl2, 5 mM  KCl, 0.3 mM KH2PO4, 0.5 mM MgCl2,
0.4 mM MgSO4, 138 mM NaCl, 4 mM NaHCO3, 0.3 mM NaHPO4,
15 mM HEPES, pH 7.1) and digitonin (0.01–1 mg  digitonin/mg pro-
tein) in a 300 l ﬁnal volume. The cells were incubated at 25 ◦C
for 4 min. As control of total release of enzymes from all compart-
ments, parasites were incubated with 0.1% Triton X-100 (v/v) in
HBSS buffer for 20 min  at 4 ◦C. The cells were then centrifuged
at 13,000 × g for 2 min  at 4 ◦C, and supernatants and insoluble
fractions (resuspended in 300 l HBSS buffer) were utilized for
western blot and activity analysis of proteins released from dif-
ferent cell compartments. The activity of enolase (E.C.4.2.1.11)
and hexokinase (E.C.2.7.1.1) was  measured as described previously
[23,24].
2.5.3. Western blot
Supernatants and insoluble fractions obtained by subcellular
fractionation with digitonin and Triton X-100 were analyzed by
10% SDS-PAGE and the proteins were subsequently transferred
from the gel to a nitrocellulose membrane. The membranes were
blocked with 5% milk in PBS for 12 h at 4 ◦C, washed with PBS and
incubated with the appropriate primary antibodies (anti-LmFH-
1 at 1:4000, anti-LmFH-2 at 1:8000 and anti-TIM at 1:50,000)
for 1 h at room temperature. After washes with PBS, the mem-
branes were incubated with as secondary antibody anti-rabbit IgG
conjugated to horseradish peroxidase (1:10,000) for 1 h at room
temperature, and visualized with the Western Blotting System
(Pierce).
2.5.4. Immunoﬂuorescence confocal microscopy
L. mexicana mexicana cells were stained with 0.3 nM Mito-
Tracker Red CMXRos (Molecular Probes) for 30 min  at 28 ◦C. Cells
were ﬁxed with 4% formaldehyde in PBS for 10 min, permeabi-
lized with 1% Triton X-100 for 15 min and incubated with 0.1 M
glycine in PBS for 12 h at 4 ◦C. The parasites were added onto
poly-lysine coated slides, incubated for 1 h at room temperature
and then incubated with 5% BSA in PBS for 45 min at 37 ◦C. Then
primary antibodies (anti-LmFH-1 at 1:1000 and anti-LmFH-2 at
1:500) in PBS containing 2% BSA were added to cells and incubated
for 45 min  at 37 ◦C. After washing with PBS, secondary antibody
(1:800 Alexa Fluor 488 anti-rabbit IgG and 1:1000 TO-PRO (DNA
marker) – Molecular Probes) in PBS containing 2% BSA were added
and incubated (45 min  at 37 ◦C). The cells were washed, mounted
in Mowiol and visualized using a Zeiss Axiovert microscope cou-
pled to an MRC-1024 confocal scanning laser imaging system (Bio
Rad).
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. Results and discussion
.1. In silico analysis of LmFH sequences
Analysis of the L. major genome sequence has led to the iden-
iﬁcation of two genes, LmjF24.0320 and LmjF29.1960, which
ncode distinct putative fumarate hydratase enzymes, LmFH-1 and
mFH-2, respectively. Sequence analysis indicated that LmFH-1 and
mFH-2 share approximately 63% identity, are both members of
lass I fumarate hydratases, and exhibit, respectively, 15% and 17%
mino-acid sequence identity to the homologous human enzyme.
These two class I fumarate hydratases are highly conserved
mong Leishmania species with the amino acid sequence identity
arying from 91 to 99% (Supplementary Figs. S1 and S2). This high
egree of sequence conservation suggests an important role for
oth isoforms within the genus Leishmania and raises the question
hat would be the speciﬁc role of each enzyme, including whether
he differences and similarities are related to their localization in
he cell, preference and afﬁnity for substrates, and levels of protein
xpression in different life-cycle forms of Leishmania.
Sequence analysis with TargetP
http://www.cbs.dtu.dk/services/TargetP) of the LmFH-1 iso-
orm allowed the identiﬁcation of a putative mitochondrial transit
eptide. Moreover a candidate type 2 peroxisomal-targeting signal
PTS2) was detected near the N-terminus (KVSHKETKY), just
ownstream of the mitochondrial transit peptide. This PTS could
otentially route the enzyme also to the glycosomes [25]. It has
een suggested that the LmFH-2 isoform might also be targeted
o glycosomes since it contains a cryptic PST1 at its C-terminal
xtremity (SKTLA) [26]. Analyzing, in addition, the sequence simi-
arity between each of the Leishmania isoforms and the orthologous
nzymes from T. brucei,  a high degree of identity can be found
etween LmFH-1 and the mitochondrial isoform TbFHm (76.4%)
nd LmFH-2 and the cytosolic isoform TbFHc (72.7%). Furthermore,
he different predicted targeting signals are almost fully conserved
mongst all Leishmania species analyzed (Supplementary Figs. S1
nd S2)  and are also present in all available corresponding FH
equences from Trypanosoma species.
These results together suggest the presence of LmFH-1 in the
itochondrion and LmFH-2 in the cytosol and do not rule out the
ossibility of a dual localization for both isoforms involving also the
lycosomes.
.2. Cloning, expression and puriﬁcation of recombinant LmFH
soforms
The open-reading frames encoding the full-length isoforms
mFH-1 and LmFH-2 were ampliﬁed by the polymerase chain
eaction (PCR) using genomic DNA as a template. The ampliﬁed
roducts of 1650 and 1707 bp encode proteins with 549 (61.1 kDa)
nd 568 (62.6 kDa) amino acids, respectively. The ampliﬁed genes
ere ligated in plasmid pET-28a, into its EcoRI and NotI restric-
ion sites. The LmFH isoforms were overexpressed as soluble, active
roteins in E. coli strain BL21(DE3). The puriﬁcation of the recom-
inant LmFH isoforms was  performed by afﬁnity chromatography
ith a Ni–NTA resin. The ﬁnal products were shown to be homoge-
eous by SDS-PAGE (Supplementary Fig. S3). Approximately 5 mg
f LmFH-1 and 10 mg  of LmFH-2 could be obtained from 1 l cultures.
.3. Circular dichroism (CD)
Far-UV circular dichroism spectra for the LmFH isoforms as a
unction of the temperature are presented in Fig. 1, panels A and C.
he circular dichroism spectra were characterized by two negative
ands at 208 and 220 nm and a positive band at 195 nm.  The mini-
um  at 220 nm was mainly attributed to helical structures, whileological Macromolecules 51 (2012) 25– 31
the negative band around 210 nm was  probably the result of a mix-
ture of the minimum at 208 nm arising from a helix structure with
the band at 215 nm originating from -sheets, which suggested a
protein structure of type /. Moreover, the comparable intensity
of the band at 208 nm and the maximum at 197 nm and minimum
around 220 nm indicate substantial quantities of -sheets.
The prediction of secondary structure content was performed
by deconvolution of the CD spectra of LmFH-1 and LmFH-2 using
K2D2 [27]. The secondary structure content was estimated as 29%
-helix and 18% -sheet for LmFH-1 and 28% -helix and 26% -
sheet for LmFH-2 (both at 20 ◦C), suggesting that these proteins,
although both belonging to class 1, may  show difference in fold-
ing. Even so, the absolute value of secondary structure content can
slightly change depending on which algorithm has been used, dif-
ferences between LmFH-1 and LmFH-2 structure content can be
clearly observed. Our results are very different from those reported
for class II fumarate hydratase, which showed a secondary struc-
ture content of 56.5% -helix and 13.1% -sheet [28], indicating that
fumarate hydratases from class I and II probably have important
structural differences.
Thermal denaturation of LmFH-1 and LmFH-2 showed that the
proteins gradually lose their secondary structure, reaching com-
plete loss of this content at 70 ◦C. The behavior of molar ellipticity
as a function of temperature at 222 (Fig. 1B) and 220 nm (Fig. 1D)
indicate melting temperatures of 56.3 ◦C for LmFH-1 and 57.7 ◦C for
LmFH-2, respectively. The thermal stability observed implies that
the LmFH isoforms can be considered thermolabile enzymes, espe-
cially when compared to the class 2 thermostable enzymes where
the Tm values can reach 80–90 ◦C [29–31].
Comparing with the initial values, analysis of the spectral res-
can after the complete run of thermal scan conﬁrmed a signiﬁcant
loss of -helix content and -strand structure, and an increase in
unordered content. In addition, macroscopically observable pre-
cipitates can be observed upon removal of LmFH samples from
the instrument. Together those results suggest the irreversibility
nature of thermal denaturation for both LmFHs.
3.4. Kinetic characterization of the LmFH isoforms
The optimum pH values for activity were estimated to be
approximately 8.7 and 9 for LmFH-1 and LmFH-2, respectively, for
the reactions in both directions. These results correlate quite well
with values reported for class I enzymes from other organisms: c.f.
fumarate hydratase from Euglena gracilis var. bacillaris (pH 8.4) [8]
and fumarate hydratase from bacterium strain MPOB (pH 8.5) [32].
Values of the kinetic parameters, Km, Vmax and kcat were deter-
mined from Lineweaver–Burk plots at pH 8.5 and 9 for LmFH-1
and LmFH-2, respectively, under anaerobic and aerobic conditions.
The Km and Vmax values of the LmFH isoforms for S-malate and
fumarate are shown in Table 1. The results demonstrate that the
Km values of LmFH-2 are approximately 2-fold higher than those
of LmFH-1 for fumarate, and 5-fold for S-malate. Our results show
that the LmFHs have higher Km values than those reported for other
class I enzymes: fumarate hydratase A from E. coli (Km = 0.6 mM
for fumarate and Km = 0.7 mM for malate) [33], fumarate hydratase
from E. gracilis var. bacillaris (Km = 0.031 mM for fumarate and
Km = 0.14 mM for malate) [8] and fumarate hydratase from bac-
terium strain MPOB (Km = 0.25 mM for fumarate and Km = 2.38 mM
for malate) [32]. This comparison between Km values suggests
that both LmFHs have afﬁnities for both substrates, fumarate and
malate, lower than the other class I FHs. The low afﬁnity for malate
has also been reported for malate dehydrogenase isozymes in L.
major [34], suggesting that the concentrations of these metabolites
in Leishmania spp. can be relatively high.
The catalytic efﬁciency estimated by determining the kcat val-
ues in both aerobic and anaerobic conditions suggests that the
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Kig. 1. Circular dichroism spectra of LmFH-1 (A) and LmFH-2 (C) at different tempe
 LmFH-1) and 220 nm (D – LmFH-2) as a function of temperature. In panels B and D
nzymes are sensitive to oxygen leading to a 2- to 12-fold reduction
n catalytic efﬁciency, depending on the isoform and the substrate
onsidered. The inactivation by oxygen is a characteristic of class I
umarate hydratases that contain a catalytically active [4Fe–4S]2+
luster [32,35],  which can be oxidized by oxygen leading to forma-
ion of an inactive [3Fe–4S]+ cluster.
.5. Intracellular localization of the LmFH isoforms
The intracellular localization of the FH isoforms was studied
n cultured insect-stage, promastigote forms of L. mexicana by
ubcellular fractionation through selective membrane permeabi-
ization with the detergent digitonin and by immunoﬂuorescence
icroscopy. The different membranes were successively perme-
bilized by increasing concentrations of digitonin. Soluble and
able 1
inetic parameters of the LmFH isoforms.
Enzyme Substrate Km (mM) Vmax (m
LmFH-1 Fumarate 2.5 ± 0.4 26.4 ± 
LmFH-1  Fumarate 1.3 ± 0.3 1.8 ± 
LmFH-2  Fumarate 5.7 ± 1.4 186.2 ± 
LmFH-2  Fumarate 1.9 ± 0.3 44.3 ± 
LmFH-1 S-Malate 2.3 ± 0.3 11.8 ± 
LmFH-1  S-Malate 1.2 ± 0.3 0.50 ± 
LmFH-2 S-Malate 12.6 ± 2.7 138.1 ± 
LmFH-2  S-Malate 5.7 ± 0.2 22.7 ± s. Thermal denaturation of LmFH proteins monitored by molar ellipticity at 222 (B
solid line is a ﬁt to a two-state model that only serves as a guide for the eye.
insoluble fractions of L. mexicana obtained with different con-
centrations of digitonin were analyzed by western blots using
anti-LmFH-1, anti-LmFH-2 and anti-TIM (triosephosphate iso-
merase, a glycosomal matrix marker protein) sera (Fig. 2A).
Soluble fractions were also utilized to measure the activities of
the enzymes hexokinase (glycosomal marker), enolase (cytosolic
marker) and fumarate hydratase (Fig. 2B). Activity assays indi-
cated that both fumarate hydratase and enolase were released from
cells treated with digitonin concentrations as low as 0.1 mg  per
mg of protein. The hexokinase activity measurements combined
with western blot analysis of TIM protein indicated that glycosomal
proteins were released starting at concentrations of 0.5 mg of digi-
tonin per mg  of protein. Monitoring of fumarate hydratase activity
indicated a small increase of released L. mexicana FH from 0.5 mg
of digitonin per mg of protein, suggesting the presence of some
ol  min−1 mg−1) kcat (s−1) Reaction condition
4.4 28.3 ± 4.7 Anaerobic
0.3 1.9 ± 0.3 Aerobic
47.5 204.2 ± 52.1 Anaerobic
4.9 48.6 ± 5.4 Aerobic
1.2 12.9 ± 1.3 Anaerobic
0.03 0.55 ± 0.03 Aerobic
18.7 151.4 ± 20.5 Anaerobic
0.5 24.9 ± 0.5 Aerobic
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Fig. 2. Subcellular localization of LmFH isoforms in L. mexicana promastigotes
by digitonin titration. (A) Western blot probed with the polyclonal antibodies
anti-LmFH-1, anti-LmFH-2 and anti-TIM to detect, respectively, LmFH-1 (61.1 kDa),













(fter  treatment of the parasites with digitonin at the indicated concentrations. (B)
nzymatic activity of fumarate hydratase, hexokinase and enolase from soluble cell
ractions obtained after treatment of the cells with digitonin.
umarate hydratase also in the glycosomes. About 40% of the hexok-
nase activity was found in the supernatant fraction, even without
etergent addition. This activity should possibly be attributed to
he hexokinase that has been reported to be associated with the
uter surface of Leishmania promastigotes, in the ﬂagellar pocket,
nd claimed to act as a hemoglobin acceptor [36].
Western blot analyses of the soluble fractions by using anti-
era to the LmFH isoforms indicated that essentially all LmFH-2
ig. 3. Subcellular localization of LmFH isoforms in L. mexicana promastigotes by immun
n  blue with TO-PRO, LmFH-1 (A) and LmFH-2 (B) in green with anti-LmFH-1 and anti-Lm
For  interpretation of the references to color in this ﬁgure legend, the reader is referred toological Macromolecules 51 (2012) 25– 31
was released already at low digitonin concentrations, conﬁrming
its cytosolic localization. However, an additional glycosomal local-
ization of a small amount of this isoform, as found by activity assays,
could not be conﬁrmed by immunoblotting. Western blot analyses
of the soluble fractions indicated that LmFH-1 was only released
when detergent levels reached 0.25 mg  of digitonin per mg  of pro-
tein and that LmFH-1 is still present in insoluble fractions even at
higher concentrations. These analyses suggested the mitochondrial
compartmentalization of LmFH-1 isoform, which is in agreement
with in silico analysis that indicates the presence of a mitochondrial
transit peptide [25].
The multiple subcellular localization of both LmFH isoforms was
also conﬁrmed by immunoﬂuorescence microscopy using speciﬁc
anti-LmFH-1 and anti-LmFH-2 sera (Fig. 3). This microscopy anal-
ysis of the L. mexicana promastigotes showed that LmFH-1 was
clearly detected with a typical mitochondrial localization. This
localization was evidenced by the intense yellow merge signal,
which corresponds to the co-localization of LmFH-1 (green ﬂuores-
cence pattern) with the red mitochondrial marker (Mito-tracker)
(Fig. 3A). Immunoﬂuorescence studies of LmFH-2 showed a dif-
fuse pattern characteristic of a cytosolic localization, and suggested
also a punctate pattern that may  be characteristic of a glycoso-
mal  localization. In addition, LmFH-2 did not co-localize with the
mitochondria (Fig. 3B). Thus, our results indicate that LmFH-1 is
found in the mitochondrion whereas LmFH-2 is located in the cyto-
sol and possibly some of it also in glycosomes. This possibly dual
localization of LmFH-2 may  be correlated to the presence of a cryp-
tic PST1 glycosomal-targeting motif at the C-terminal extremity
(SKTLA) that may, under certain conditions, be decrypted to become
a functional PTS as suggested previously [26].
LmFH isoforms are important for the energy metabolism in
Leishmania through the production of fumarate in cytosol, gly-
cosomes and mitochondrion. Fumarate has an important role in
several steps of the intermediary metabolism of trypanosomatids.
In the cytosol, fumarate acts as a substrate of dihydroorotate
dehydrogenase, an enzyme that participates in the de novo pyrimi-
dine biosynthesis pathway [14]. In mitochondrion and glycosomes,
fumarate may, like in procyclic T. brucei,  participate in the succinic
fermentation pathways acting as a substrate of the mitochondrial
[37] and glycosomal [16] isoforms of fumarate reductase, respec-
tively. Contrary to the situation in T. brucei where no TCA cycle
activity has been detected and instead parts of the cycle act inde-
pendently [38], LmFH-1 may  also participate in the TCA cycle to
oﬂuorescence microscopy. Mitochondria are labeled in red with Mito-tracker, DNA
FH-2 respectively, by using Alexa Fluor 488 anti-rabbit as the secondary antibody.























































[P.R. Feliciano et al. / International Journa
atalyze the reversible reaction of fumarate to malate. Recent stud-
es showed that the full catabolism of glucose to carbon dioxide,
hrough the operation of a complete TCA cycle, is essential for the
rowth of Leishmania promastigotes [39].
The vital role of fumarate hydratases in a wide range of cellular
rocesses: pyrimidine biosynthesis, succinic fermentation and TCA
ycle, as well as the fact that fumarate hydratases from different
eishmania species share very high sequence identity indicate that
umarate hydratases may  be considered for exploitation as targets
or the development of antileishmanial drugs. The development of a
rotocol to overproduce soluble and active enzymes, in conjunction
ith the results from the structural, kinetics and subcellular local-
zation experiments presented in this paper, provides an important
asis for further crystallographic and functional studies. Work on
hese topics is currently in progress.
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